Targets › SFLT1
1 program from 1 company in 1 trial: 1 Phase 1; Ophthalmology; next expected readout Mar 2029.
Open in Phaseline: the race on SFLT1, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Oxford BioMedica | RetinoStat Adeno-associated virus (AAV) vector delivering soluble fms-like tyrosine kinase-1 (sFLT1) | SFLT1 | Phase 1 | Age-Related Macular Degeneration | Mar 2029 |
Age-Related Macular Degeneration (1)
small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.